ArticleFrontiers in cellular and infection microbiology2026
Early prediction of plastic bronchitis in pediatric patients with
Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Explainable machine learning for diagnosing severeFrontiers in pediatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Methods: This retrospective cohort study involved 307 pediatric patients with MPP who underwent bronchoscopy intervention from April 2023, to June 2025.Patients were randomly split into training and test sets (7:3). After feature selection using LASSO and Boruta algorithms, four algorithms, namely, extreme gradient boosting (XGBoost), logistic regression, random forest, and support vector machine, were employed to construct machine learning (ML) models through 5-fold cross-validation. Model performance was evaluated using the area under the curve (AUC), calibration curves, and decision curve analysis (DCA). The best-performing ML was selected using AUC, and feature importance in the model was ranked using SHapley Additive exPlanations (SHAP). Finally, a web-based risk predictor was constructed to facilitate user operability. Results: MPP children with PB demonstrated more significant abnormalities in inflammation- and nutrition-related indices compared to those without PB. The XGBoost algorithm exhibited the best predictive performance, surpassing other models (logistic regression, random forest, and support vector machine) with an AUC of 0.948 (95% CI: 0.919-0.973), a sensitivity of 0.904, and a specificity of 0.858 on the training set, and an AUC of 0.905 (95% CI: 0.843-0.957), a sensitivity of 0.812, and a specificity of 0.852 on the test set. This algorithm also presented good calibration and net clinical benefit. SHAP analysis identified the retinol-binding protein 4 level, M. pneumoniae cycle-threshold value, D-dimer level, fever duration before admission, C-reactive protein-to-albumin ratio, and presence of pleural effusion as key predictors. To facilitate the clinical adoption, a freely accessible online calculator has been developed (https://plasticbronchitis.shinyapps.io/plastic_bronchitis_risk_calculator/). Conclusion: The developed interpretable ML models deployed in the network application can help clinicians identify children at high risk of developing PB earlier and tailor timely bronchoscopy intervention and nutritional support as well as anti-inflammatory therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.